Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan-Mar;47(1):e2025E005.
doi: 10.1590/2175-8239-JBN-2025-E005en.

Thymoglobulin induction in kidney transplantation: real-world cost-effectiveness in Brazil's public healthcare system

[Article in English, Portuguese]
Roberto Ceratti Manfro  1   2
Affiliations
Editorial

Thymoglobulin induction in kidney transplantation: real-world cost-effectiveness in Brazil's public healthcare system

[Article in English, Portuguese]
Roberto Ceratti Manfro. J Bras Nefrol. 2025 Jan-Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The author declares no conflict of interest.

References

    1. Bessa AB, Cristelli MP, Felipe CR, Foresto RD, Fonseca MC, Medina-Pestana J, et al. Real-world setting cost-effectiveness analysis of thymoglobulin versus no induction therapy in kidney transplant recipients with low risk for graft loss. Braz J Nephrol. 2024;47(1):e20240060. doi: 10.1590/2175-8239-JBN-2024-0060en. - DOI - PMC - PubMed
    1. Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, et al. Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am J Transplant. 2015;15(10):2655–64. doi: 10.1111/ajt.13327. - DOI - PubMed
    1. Paula MI, Bowring MG, Shaffer AA, Garonzik-Wang J, Bessa AB, Felipe CR, et al. Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit anti-thymocyte globulin without CMV prophylaxis: a cohort single-center study. Transpl Int. 2021;34(2):339–52. doi: 10.1111/tri.13800. - DOI - PMC - PubMed
    1. Custodio LFP, Martins SBS, Viana LA, Cristelli MP, Requião-Moura L, Chow CYZ, et al. Efficacy and safety of single-dose anti-thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: a retrospective comparative cohort study. J Pediatr Transplant. 2024;28(3):e14713. doi: 10.1111/petr.14713. - DOI - PubMed
    1. Machado FP, Rauber N, Vicari AR, Bauer AC, Manfro RC. Single-dose antithymocyte globulin in standard immunological risk kidney transplant recipients: efficacy and kinetics of peripheral blood CD3+ T lymphocyte modulation. J Nephrol. 2024;37(6):1487–96. doi: 10.1007/s40620-023-01792-9. - DOI - PubMed

Publication types

LinkOut - more resources